Nextar Chempharma Solutions Overview
Nextar Chempharma Solutions specializes in the development of drugs and medical devices and manufacturing. Nextar's proprietary Brain Targeted Liposomes platform can facilitate targeted delivery of versatile drugs across the blood-brain barrier and into the brain. The drug delivery platform is a combination of a liposomal vehicle with the targeter complex that allows blood-brain barrier permeation and brain-specific delivery of versatile therapeutic agents.
Latest News
נקסטר-תוצאות סופיות חיוביות של ניסוי בעכברים להדגמת יעילות טיפול בסרטן מוח מסוג גליובלסטומה בהתבסס על פלטפורמת ה-BTLS של החב'
growth-positive
נקסטייג' חתמה על הסכם למיזוג נקסטר לפי שווי של לא פחות מ-78 מיליון שקל
Nextage, a company that develops drugs based on psychedelic substances to treat brain diseases and chronic pain, has announced a merger with Nexstar through a stock exchange. Post-merger, Nexstar shareholders will hold approximately 74.99% of Nextage. The merger is expected to significantly increase Nextages revenues and add a significant technological pipeline, with an emphasis on the brain field. Nexstar, a private company involved in the development and manufacturing of chemical services for drugs and medical devices, has been operating for 15 years.
Acquired-by
growth-positive
Cannabis Pharmaceutical Outfit Nextage Wants to Raise $15 Million in Canada
Nextage Cannabis Innovation Ltd. is raising up to $15 million from private Canadian entities at a company valuation of $50 million. The funding will be used to build a manufacturing facility in Israel and continue developing the companys pipeline. Nextage is also in the process of merging with Micromedic Technologies Ltd. and aims to list in Canada or the U.S.
InvestmentAcquisition
growth-positive
Israel's Nextar setting up medical cannabis incubator
Nextar, a leading company in drug formulations, is expanding into medical cannabis formulations. The company will invest in setting up a development center and incubator for medical cannabis products. Nextar will provide cannabis development services to external companies and overseas companies, and will develop independent cannabis products. The company will invest $5 million in the venture and has signed an agreement with Budding Tech, an Australian fund for the medical cannabis sector. The incubator, called Nextage, will accept six companies a year and initially invest $100,000-400,000 in each company. Nextars expansion into the medical cannabis field aims to address the lack of development in the industry and improve the reproducibility of cannabis products.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $370K |
| Last funding | $370K |
| Stage | Mature |
| Rounds | 1 |
| Investors | 0 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.nextar.co.il |
Locations
Einstein 13, Ness Ziona, Israel
Photos & Videos
1 item(s)
